期刊文献+

多发性骨髓瘤2015年NCCN指南更新及解读 被引量:35

下载PDF
导出
摘要 多发性骨髓瘤(Multiple myeloma,MM)是一种浆细胞克隆性疾病,可导致高钙血症、贫血、肾功能损伤、骨破坏等症状。根据美国的统计数据,MM占所有癌症的1%,占血液系统恶性肿瘤的10%。近年来,随着治疗MM新药的不断问世,MM的治疗有了飞速的进展,各种治疗方案不断更新。2015年3月,美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)发布了多发性骨髓瘤的最新诊疗指南,对于MM的检测项目、疗效标准、进展和复发MM的治疗均有所更新,特别是对于复发难治性MM的治疗更新成为本版指南的亮点。本文就此版指南的相关内容进行详细解读。
出处 《实用药物与临床》 CAS 2015年第8期881-885,共5页 Practical Pharmacy and Clinical Remedies
  • 相关文献

参考文献9

  • 1Siegel R,Naishadham D,Jemal A.Cancer statistics[J].CA Cancer J Clin,2012,62:10-29.
  • 2Palumbo A,Rajkumar SV,San Miguel JF,et al.International Myeloma Working Group consensus statement for the management,treatment,and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation[J].J Clin Oncol,2014,32:587-600.
  • 3Palumbo A,Falco P,Corradini P,et al.Melphalan,prednisone,and lenalidomide treatment for newly diagnosed myeloma:a report from the GIMEMA-Italian Multiple Myeloma Network[J].J Clin Oncol,2007,25:4459-4465.
  • 4Palumbo A,Cavallo F,Gay F,et al.Autologous transplantation and maintenance therapy in multiple myeloma[J].N Engl J Med,2014,371:895-905.
  • 5Atadja P.Development of the pan-DAC inhibitor panobinostat(LBH589):successes and challenges[J].Cancer Lett,2009,280:233-241.
  • 6San-Miguel JF,Hungria VT,Yoon SS,et al.Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma:a multicentre,randomised,doubleblind phase 3 trial[J].Lancet Oncol,2014,15:1195-1206.
  • 7Stewart AK,Rajkumar SV,Dimopoulos MA,et al.Carfilzomib,lenalidomide,and dexamethasone for relapsed multiple myeloma[J].N Engl J Med,2015,372:142-152.
  • 8Siegel DS,Martin T,Wang M,et al.A phase 2 study of singleagent carfilzomib(PX-171-003-A1)in patients with relapsed and refractory multiple myeloma[J].Blood,2012,120:2817-2825.
  • 9Lonial S,Dimopoulos M,Palumbo A,et al.Elotuzumab therapy for relapsed or refractory multiple myeloma[J].N Engl J Med,2015,373(7):621-631.

同被引文献313

  • 1邓银芬,袁红建.硼替佐米联合化疗治疗多发性骨髓瘤的疗效观察[J].世界最新医学信息文摘,2019,0(88):168-168. 被引量:1
  • 2王爱武,刘娅,雒琪,翟红,王福文,王梅.独活寄生汤抗炎、镇痛作用的药效学研究[J].中国实验方剂学杂志,2008,14(12):61-64. 被引量:139
  • 3张骏,邓宏宇,巫刚.多发性骨髓瘤患者血钙异常的临床分析[J].中华血液学杂志,2005,26(4):246-247. 被引量:20
  • 4全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:706
  • 5Eslick R,Talaulikar D.Multiple myeloma:from diagnosis to treatment[J].Aust Fam Physician,2013,42(10):684-688.
  • 6Tosi P,Tomassetti S,Merli A,et al.Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions[J].Ther Adv Hematol,2013,4(1):37-41.
  • 7Katzmann JA,Clark RJ,Abraham RS,et al.Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains:relative sensitivity for detection of monoclonal light chains[J].Clin Chem,2002,48(9):1437-1444.
  • 8Kraj M.Immunoglobulin heavy chain/light chain pairs(HLC,HevyliteTM)assays for diagnosing and monitoring monoclonal gammopathies[J].Adv Clin Exp Med,2014,23(1):127-133.
  • 9Lahuerta JJ,Martinez-Lopez J,Serna JD,et al.Remission status defined by immunofixation vs.electrophoresis after autologous transplantation has a major impact on the outcome of multiple myelom patients[J].Br J Haematol,2000,109(2):438-446.
  • 10LEE N, LEE H, MOON S Y, et al.Adverse Prognostic Impact of Bone Marrow Microvessel Density in Multiple Myeloma [J].Ann Lab Med, 2015,35(6) :563-569.

引证文献35

二级引证文献144

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部